LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Novo Nordisk will advance next-generation obesity candidate amycretin into late-stage development, both as injection and oral pill, with phase III program planned to initiate during first quarter of 2026

  80% confidence

• Mounjaro and Zepbound account for more than 50% of the company's total revenues

  80% confidence

• Eli Lilly is a great stock to have in one's portfolio, given its significant price appreciation, product and pipeline portfolio, robust growth prospects and bullish analyst sentiment

  80% confidence

• The obesity market is huge and multiple players can co-exist

  80% confidence

• Eli Lilly is a Zacks Rank #1 (Strong Buy) stock

  80% confidence

• Eli Lilly expects data readouts from three phase III studies on retatrutide for treating obesity in the second half of 2026

  80% confidence

• Mounjaro and Zepbound are expected to continue to see strong demand in 2026

  80% confidence

• Structure Therapeutics expects to initiate late-stage program of aleniglipron in obesity around mid-2026

  80% confidence

• Eli Lilly plans to file regulatory applications for orforglipron in type II diabetes in the first half of 2026

  80% confidence

• Despite NVO having the lead in the oral obesity market, Lilly may be able to close the gap fast once orforglipron is approved by the FDA in 2026

  80% confidence

• Eli Lilly expects new drugs (Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla), along with expanded use of existing drugs, to drive sales growth in 2026

  80% confidence

• Novo Nordisk expects to launch the Wegovy pill in early January 2026

  80% confidence